Dr. Ian Walters CEO of Portage Biotech, is building a pipeline of novel immunotherapies for the treatment of cancer particularly for patients who do not respond to current therapies. The key is stimulating a type of immune cell called invariant natural killer T-cell which works with the adaptive immune system to create a broad immune response and stronger immune surveillance to help stop cancer from forming in the body. Having contributed to bringing five new blockbuster cancer drugs to patients, Ian and his team are working to hit all key components for every different tumor type for a long-term response and possible cure. They think their drug could have potential in settings that wouldn't respond to just pure NK cell therapy.
top of page
bottom of page